How 500 Shares of Pfizer and Johnson & Johnson Could Pay $3,540 a Year

A 500-share position in Pfizer and Johnson & Johnson can look simple at first: buy two major healthcare stocks, collect quarterly dividends and let the income build through the year. At the prices used in this dividend-income example, that combination could generate about $3,540 a year in annual dividend income before taxes.

That estimate is based on owning 500 shares of Johnson & Johnson and 500 shares of Pfizer, not 500 shares split between the two companies.

The appeal is clear. Both companies are large healthcare names with long histories of paying shareholders. But they are not the same kind of dividend story. Johnson & Johnson offers the steadier profile, backed by decades of annual dividend increases. Pfizer offers the higher yield, but that yield reflects a stock still working through pressure after the post-COVID revenue reset.

The dividend math behind the $3,540 estimate

The calculation starts with the annual dividend per share. Johnson & Johnson’s quarterly dividend was raised to $1.34 per share, equal to an annualized payout of $5.36 per share. A 500-share position would therefore produce about $2,680 a year in dividend income before taxes.

That increase also marked Johnson & Johnson’s 64th consecutive year of dividend growth, a record that keeps the company among the market’s most established dividend payers.

Pfizer’s dividend is different. Its quarterly payout of $0.43 per share equals an annualized dividend of $1.72 per share. A 500-share position would produce about $860 a year in dividends before taxes.

Using the prices from the example, Johnson & Johnson traded near $228.39 per share, making 500 shares worth about $114,195. Pfizer traded near $25.21 per share, making 500 shares worth about $12,605. That puts the combined investment near $126,800, with a blended dividend yield of about 2.79%.

That number is useful, but it should not be treated as guaranteed income. Dividends are approved by company boards and can change. Stock prices can also fall, meaning an investor can collect dividends while still seeing the value of the portfolio decline.

JNJ brings stability while Pfizer brings higher yield

Johnson & Johnson is the steadier part of this two-stock income example. The company operates through Innovative Medicine and MedTech, giving it exposure to prescription drugs, medical devices and hospital-related demand. In the figures used for the article, Innovative Medicine revenue reached $15.426 billion in the first quarter of 2026, up 11.2% year over year. MedTech added $8.636 billion, up 7.7%.

The dividend strength comes from scale, cash generation and balance-sheet quality. Johnson & Johnson has historically been viewed as one of the more defensive healthcare stocks because demand for many of its products is less tied to the economic cycle than consumer discretionary spending.

Pfizer carries a more complicated story. Its higher yield can attract income investors, but it also reflects market concern after the decline in COVID-related products. Comirnaty and Paxlovid are no longer delivering the same level of pandemic-era revenue, so investors are focused on Pfizer’s core medicines, oncology pipeline, acquisitions and patent timelines.

In the article’s figures, Pfizer’s first-quarter 2026 revenue reached $14.451 billion. Several non-COVID products helped support the business: Eliquis revenue rose 13% to $2.166 billion, Vyndaqel increased 8% to $1.602 billion, and Padcev jumped 39%.

For readers already following Pfizer’s dividend and pipeline debate, this earlier Swikblog report on Pfizer stock, its dividend yield and drug pipeline outlook gives useful added context on how investors have been weighing the stock’s income appeal against its growth concerns.

The comparison is straightforward. Johnson & Johnson is the lower-yield, higher-stability dividend compounder. Pfizer is the higher-yield stock with more uncertainty attached to the payout story. One may appeal more to conservative dividend investors, while the other may appeal to investors willing to accept more business risk for a larger current yield.

Dividend income may also be taxable depending on the investor’s country, account type and holding period. That means the $3,540 figure should be viewed as a pre-tax estimate, not guaranteed cash an investor will keep in full.

Concentration is another risk. A portfolio built around only two healthcare stocks can still be exposed to company-specific setbacks, drug-pipeline disappointments, litigation, regulation or valuation pressure. Investors who rely on dividends often spread income across several sectors instead of depending heavily on one or two names.

Income investors comparing healthcare payouts with other sectors may also find context in Swikblog’s coverage of Shell’s dividend yield and buyback strategy, where shareholder returns are shaped by a very different mix of commodity prices, cash flow cycles and capital spending.

The key point is that the $3,540 annual dividend estimate is possible based on the dividend rates used, but the quality of that income depends on payout durability. Johnson & Johnson brings the stronger dividend-growth record, while Pfizer brings the higher current yield and higher uncertainty. For long-term investors, the better decision comes from weighing both income and risk rather than chasing the largest yield alone.

Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.